利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.029 秒)

    Substituted pyrimidine derivatives
    2.
    发明申请
    Substituted pyrimidine derivatives 失效
    取代的嘧啶衍生物

    公开(公告)号：US20050101613A1

    公开(公告)日：2005-05-12

    申请号：US10839055

    申请日：2004-05-05

    申请人： Jeffrey Corbett ,  Michael Ennis ,  Kristine Frank ,  Jian-Min Fu ,  Robert Hoffman ,  Patrick Verhoest

    发明人： Jeffrey Corbett ,  Michael Ennis ,  Kristine Frank ,  Jian-Min Fu ,  Robert Hoffman ,  Patrick Verhoest

    IPC分类号： C07D213/72 ,  C07D239/42 ,  A61K31/506 ,  A61K31/4439 ,  C07D43/02

    CPC分类号： C07D239/42 ,  C07D213/72

    摘要： This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF, receptors, including human CRF, receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

    摘要翻译： 本发明涉及式I化合物，其立体异构体，其药学上可接受的盐，其前药或其前药的药学上可接受的盐。 该化合物与CRF，受体（包括人类CRF）受体相互作用。 本发明还涉及使用本发明化合物治疗病症或病症的方法，所述疾病或病症的治疗可以通过拮抗CRF受体如CNS疾病或疾病，特别是焦虑相关疾病例如焦虑来实现或促进 ，以及心理障碍如重度抑郁症。

    SUBSTITUTED PYRIMIDINE DERIVATIVES
    4.
    发明申请
    SUBSTITUTED PYRIMIDINE DERIVATIVES 审中-公开
    取代的吡咯烷衍生物

    公开(公告)号：US20060217398A1

    公开(公告)日：2006-09-28

    申请号：US11424073

    申请日：2006-06-14

    申请人： Jeffrey Corbett ,  Micheal Ennis ,  Kristine Frank ,  Jian-Min Fu ,  Robert Hoffman ,  Patrick Verhoest

    发明人： Jeffrey Corbett ,  Micheal Ennis ,  Kristine Frank ,  Jian-Min Fu ,  Robert Hoffman ,  Patrick Verhoest

    IPC分类号： A61K31/506 ,  A61K31/4439

    CPC分类号： C07D239/42 ,  C07D213/72

    摘要： This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

    摘要翻译： 本发明涉及式I化合物，其立体异构体，其药学上可接受的盐，其前药或其前药的药学上可接受的盐。 这些化合物与CRF1受体（包括人CRF 1受体）相互作用。 本发明还涉及使用本发明化合物治疗病症或病症的方法，所述疾病或病症的治疗可以通过拮抗CRF受体如CNS疾病或疾病，特别是焦虑相关疾病例如焦虑来实现或促进 ，以及心理障碍如重度抑郁症。

    Substituted aryl 1,4-pyrazine derivatives
    7.
    发明申请
    Substituted aryl 1,4-pyrazine derivatives 审中-公开
    取代的芳基1,4-吡嗪衍生物

    公开(公告)号：US20060211710A1

    公开(公告)日：2006-09-21

    申请号：US11363009

    申请日：2006-02-27

    申请人： Patrick Verhoest ,  Robert Hoffmann

    发明人： Patrick Verhoest ,  Robert Hoffmann

    IPC分类号： A61K31/496 ,  C07D403/02

    CPC分类号： C07D401/04

    摘要： The invention is directed to compounds of Formula I, described herein, as well as pharmaceutically acceptable salts thereof, which act as CRF1 antagonists and are useful in the treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases.

    摘要翻译： 本发明涉及本文所述的式I化合物及其药学上可接受的盐，其作为CRF 1拮抗剂，并且可用于治疗与CRF 1受体，包括CNS相关疾病和疾病。

    Heteroaromatic quinoline compounds
    8.
    发明申请
    Heteroaromatic quinoline compounds 有权
    杂芳族喹啉化合物

    公开(公告)号：US20060154931A1

    公开(公告)日：2006-07-13

    申请号：US11326221

    申请日：2006-01-05

    申请人： Patrick Verhoest ,  Christopher Helal ,  Dennis Hoover ,  John Humphrey

    发明人： Patrick Verhoest ,  Christopher Helal ,  Dennis Hoover ,  John Humphrey

    IPC分类号： A61K31/506 ,  A61K31/498 ,  A61K31/4709 ,  C07D403/14 ,  C07D401/14

    CPC分类号： C07D401/14 ,  C07D413/14

    摘要： The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

    摘要翻译： 本发明涉及用作有效磷酸二酯酶（PDE）抑制剂的杂芳族化合物。 特别地，本发明涉及作为PDE10的选择性抑制剂的所述化合物。 本发明还涉及制备所述化合物的中间体; 包含所述化合物的药物组合物; 以及所述化合物在治疗某些中枢神经系统（CNS）或其它疾病的方法中的用途。

    BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS
    9.
    发明申请
    BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS 审中-公开
    作为PDE10抑制剂的双相异构体化合物

    公开(公告)号：US20070155779A1

    公开(公告)日：2007-07-05

    申请号：US11619218

    申请日：2007-01-03

    申请人： Patrick Verhoest ,  Christopher Helal

    发明人： Patrick Verhoest ,  Christopher Helal

    IPC分类号： A61K31/4745 ,  A61K31/4439 ,  C07D471/02 ,  C07D403/14

    CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/06 ,  C07D513/04

    摘要： The invention pertains to bicyclic heteroaryl compounds that serve as effective phosphodiesterase (PDE) inhibitors The invention also relates to compounds which are selective inhibitors of PDE-10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.

    摘要翻译： 本发明涉及用作有效磷酸二酯酶（PDE）抑制剂的双环杂芳基化合物本发明还涉及作为PDE-10的选择性抑制剂的化合物。 本发明还涉及制备这些化合物的中间体; 包含这些化合物的药物组合物; 以及这些化合物在治疗某些中枢神经系统（CNS）或其他疾病的方法中的应用。 本发明还涉及用于治疗神经变性和精神疾病的方法，例如包括缺乏认知作为症状的精神病和病症。